SAB Biotherapeutics Reports Encouraging Phase 1 Data for SAB-142 in Type 1 Diabetes

Key Points and Potentially Price-Sensitive Developments for Investors

Overview

SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced additional data from its Phase 1 clinical trial of SAB-142, a fully human anti-thymocyte immunoglobulin (hATG) designed for the treatment of type 1 diabetes (T1D) and other autoimmune diseases.

Key Findings from Phase 1 Trial

• Early Signals of C-Peptide Preservation: In the established T1D adult patient cohort (n=6), SAB-142 treated participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline, indicating preservation of endogenous insulin production. In contrast, the placebo participant demonstrated a decline in C-peptide, in line with disease progression.
• Supportive Biomarker Evidence: The preservation of C-peptide was supported by biomarker evidence of T cell exhaustion, consistent with the anticipated mechanism of action for SAB-142.
• Patient Demographics: The trial involved adults aged 19–40 years with established Stage 3 T1D (diagnosed within 28–40 months prior to randomization). All had residual beta cell function (C-peptide >0.2 nmol/L) and at least one T1D autoantibody.
• Study Design: The Phase 1 study was randomized, double-blind, placebo-controlled, and included a single-ascending dose and redose, adaptive design. Participants received SAB-142 at 2.5 mg/kg or placebo.
• Safety: The study met its primary safety objectives, establishing a favorable safety and pharmacodynamic profile for SAB-142.

Expert Commentary

“People living with T1D need novel treatment options to alter the course of their disease, and we know that the preservation of C-peptide as a marker of endogenous insulin production has a positive clinical effect. While exploratory and early, the initial C-peptide data are encouraging and exactly the type of signal I hope to see at this stage. Additionally, these clinical observations were supported by biomarker evidence of T cell exhaustion consistent with prior studies, strengthening confidence that the therapy is engaging its intended biological mechanism,” said Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology, University of Florida.

Potentially Price-Sensitive Information for Investors

• Transition to Phase 2b “SAFEGUARD” Trial: Based on the positive safety and early efficacy signals, SAB-142 has advanced to a registrational Phase 2b trial (SAFEGUARD), which is currently enrolling adults, adolescents, and pediatric patients with new-onset, Stage 3 T1D globally. Topline data from this trial are expected in the second half of 2027.
• Clinical Relevance: The ability to preserve C-peptide production is a critical endpoint in T1D, as it is directly related to the preservation of the patient’s own insulin production and better long-term outcomes.
• Potential to Change Standard of Care: SAB-142 is being positioned as a potentially best-in-class, disease-modifying immunotherapy for T1D, with a novel, fully human antibody approach that may offer advantages over the current rabbit-derived ATG products.
• Innovative Production Platform: SAB BIO’s proprietary technology uses genetically engineered transchromosomic cattle (Tc-Bovine™) to produce high-potency, human immunoglobulin G (hIgG) antibodies, eliminating the need for human donors or convalescent plasma.
• Ongoing Communication with the T1D Community: SAB BIO is proactively sharing early data with investigators, clinicians, and patients, providing greater transparency and aiming to build community engagement and support.

Additional Details

• SAFEGUARD Trial Design: Multi-center, double-arm Phase 2b study with dose-ranging (Part A – adults; Part B – randomized, double-blind, placebo-controlled in broader population). Patients receive two infusions of SAB-142 or placebo, six months apart, with all eligible for a 12-month long-term extension.
• Mechanism of Action: Like rabbit ATG, SAB-142 targets multiple immune cells, especially T-lymphocytes involved in the autoimmune destruction of pancreatic beta cells, aiming to preserve endogenous insulin production.
• Previous Clinical Evidence: The company referenced the TN19 study, which modeled historical placebo declines in C-peptide, and SAB-142 showed a positive divergence from this trajectory.
• Webinar for Further Information: A recorded expert webinar by Dr. Michael J. Haller reviewing Phase 1 data is available on SAB BIO’s website, alongside the full Phase 1 data set.

Conclusion

SAB Biotherapeutics’ announcement of its encouraging Phase 1 results for SAB-142, including early signals of C-peptide preservation and supportive mechanistic biomarkers, represents a potentially significant milestone for the company and for patients with type 1 diabetes. The rapid progression into a global Phase 2b trial underscores management’s confidence in the therapy’s disease-modifying potential. Given the high unmet need in T1D and the prospect for a novel, best-in-class therapeutic, these developments could be materially relevant for shareholders and may impact share valuation as further clinical milestones are reached.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors should review SAB Biotherapeutics’ filings with the SEC and consult with their financial advisors before making investment decisions.

View SAB Biotherapeutics, Inc. Historical chart here